Hennigsdorf, Germany 

Pantherna Therapeutics GmbH, a leading innovator in advanced LNP technologies for mRNA-based therapeutics, is pleased to announce the upcoming grant of Canadian Patent No. 3,108,670. The patent, titled “Recombinant Nucleic Acid Construct,” further strengthens the company’s global intellectual property protection.

This Canadian patent follows recent grants from the Korean, European, and Japanese patent offices. The continued expansion of Pantherna’s patent portfolio underscores the broad applicability and innovative nature of its technology for the efficient expression of therapeutic proteins.

Dr. Ansgar Santel, Chief Executive Officer of Pantherna Therapeutics, commented:
“Securing patent protection in Canada—alongside our recently granted patents in Korea, Europe, and Japan—is another significant milestone for Pantherna. These grants collectively reinforce our presence in key international markets and validate the innovative potential of our technology.”